{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:44:51Z","timestamp":1791837891342,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009752","name":"Futurum Academy of Health and Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jgo.2026.104639","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:07:02Z","timestamp":1791752822000},"page":"104639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Follow-Up after adjuvanT CDK4\/6i Use in oldeR brEst cancer patients - aspects on geriatric screening, toxicities, and quality of life (FUTURE): A prospective observational cohort study"],"prefix":"10.1016","volume":"18","author":[{"given":"Johanna","family":"Sj\u00f6berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Robert","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Ekstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilke","family":"Cikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Valachis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2026.104639_bb0005","author":"Nationellt v\u00e5rdprogram br\u00f6stcancer"},{"issue":"22","key":"10.1016\/j.jgo.2026.104639_bb0010","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration","volume":"22","author":"Talarico","year":"2004","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jgo.2026.104639_bb0015","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2017.35.15_suppl.10009","article-title":"FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. Food and Drug Administration","volume":"35","author":"Singh","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2026.104639_bb0020","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1200\/JCO.2003.09.124","article-title":"Barriers to clinical trial participation by older women with breast cancer","volume":"21","author":"Kemeny","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2026.104639_bb0025","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.jgo.2026.104639_bb0030","article-title":"Co-targeting CDK4\/6 and AKT with endocrine therapy prevents progression in CDK4\/6 inhibitor and endocrine therapy-resistant breast cancer","volume":"12","author":"Alves","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jgo.2026.104639_bb0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2026.104639_bb0040","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast Cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jgo.2026.104639_bb0045","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant Palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2026.104639_bb0050","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast Cancer-the Penelope-B trial","volume":"39","author":"Loibl","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2026.104639_bb0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2026.104639_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105858","article-title":"Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival","volume":"10","author":"Crown","year":"2025","journal-title":"ESMO Open"},{"issue":"24","key":"10.1016\/j.jgo.2026.104639_bb0065","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1200\/JCO.2007.10.9710","article-title":"Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia group B experience","volume":"25","author":"Muss","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2026.104639_bb0070","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jgo.2020.09.004","article-title":"Treatment patterns, risk for hospitalization and mortality in older patients with triple negative breast cancer","volume":"12","author":"Valachis","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2026.104639_bb0075","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.20.02063","article-title":"Development and validation of a risk tool for predicting severe toxicity in older adults receiving chemotherapy for early-stage breast cancer","volume":"39","author":"Magnuson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2026.104639_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2025.102213","article-title":"Breast cancer in older patients: can CDK 4\/6 inhibitors make the difference in the adjuvant setting?","volume":"16","author":"Dottorini","year":"2025","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2026.104639_bb0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/bs.acr.2022.03.005","article-title":"Nephrotoxicity in cancer treatment: an update","volume":"155","author":"Chen","year":"2022","journal-title":"Adv Cancer Res"},{"issue":"8","key":"10.1016\/j.jgo.2026.104639_bb0090","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1634\/theoncologist.2010-0348","article-title":"Cardiovascular complications of breast cancer therapy in older adults","volume":"16","author":"Shenoy","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2026.104639_bb0095","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejca.2020.11.022","article-title":"Bridging the age gap in breast cancer: impact of chemotherapy on quality of life in older women with early breast cancer","volume":"144","author":"Battisti","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.jgo.2026.104639_bb0100","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(20)30741-5","article-title":"Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG)","volume":"22","author":"Biganzoli","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.jgo.2026.104639_bb0105","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2026.104639_bb0125","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2026.104639_bib176","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1046\/j.1532-5415.2001.49281.x","article-title":"The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community","volume":"49","author":"Saliba","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.jgo.2026.104639_bb0120","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jgo.2021.01.008","article-title":"Predicting disease-related and patient-reported outcomes in older patients with breast cancer - a systematic review","volume":"12","author":"van der Plas-Krijgsman","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2026.104639_bb0130","doi-asserted-by":"crossref","first-page":"100612","DOI":"10.1016\/S2666-7568(24)00118-1","article-title":"Association between geriatric 8 frailty and health-related quality of life in older patients with cancer (PROGNOSIS-G8): a Danish single-Centre, prospective cohort study","volume":"5","author":"Ditzel","year":"2024","journal-title":"Lancet Healthy Longev"},{"issue":"6","key":"10.1016\/j.jgo.2026.104639_bb0135","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jgo.2019.04.016","article-title":"A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer","volume":"10","author":"van Walree","year":"2019","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2026.104639_bb0140","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jgo.2015.02.005","article-title":"Estimating the risk of chemotherapy toxicity in older patients with cancer: the role of the vulnerable elders Survey-13 (VES-13)","volume":"6","author":"Luciani","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jgo.2026.104639_bb0145","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.2021.39.15_suppl.1012","article-title":"PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: baseline characteristics and safety evaluation","volume":"39","author":"Caillet","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2026.104639_bb0150","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.22.01440","article-title":"Low-intensity adjuvant chemotherapy for breast cancer in older women: results from the prospective multicenter HOPE trial","volume":"41","author":"Sedrak","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2026.104639_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/s44276-024-00108-z","article-title":"Overall survival after CDK4\/6 inhibitor dose reduction in women with metastatic breast cancer","volume":"2","author":"Bjerrum","year":"2024","journal-title":"BJC Rep"},{"issue":"10","key":"10.1016\/j.jgo.2026.104639_bb0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.39116","article-title":"Chemotherapy-related toxic effects and quality of life and physical functioning in older patients","volume":"6","author":"Baltussen","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"16_suppl","key":"10.1016\/j.jgo.2026.104639_bb0165","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2023.41.16_suppl.501","article-title":"Efficacy and safety results by age in monarchE: adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC)","volume":"41","author":"Hamilton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2026.104639_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-024-00639-1","article-title":"Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study","volume":"10","author":"Goetz","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"37","key":"10.1016\/j.jgo.2026.104639_bb0175","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1080\/14796694.2024.2413841","article-title":"Implementing geriatric assessment for dose optimization of CDK4\/6 inhibitors in older breast cancer patients","volume":"20","author":"Valachis","year":"2024","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2026.104639_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE prospective Multicenter cohort study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.jgo.2026.104639_bb0115","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2009.25.9978","article-title":"Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13","volume":"28","author":"Luciani","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826017960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826017960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:47:56Z","timestamp":1791834476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406826017960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S1879406826017960"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.104639","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follow-Up after adjuvanT CDK4\/6i Use in oldeR brEst cancer patients - aspects on geriatric screening, toxicities, and quality of life (FUTURE): A prospective observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.104639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104639"}}